Complex Generic Sponsors Not Using US FDA-EMA Parallel Scientific Advice Program

After nearly two years, the program has received only two requests, driving FDA officials to try to boost interest.

US and EU collaboration
FDA officials believe the FDA-EMA parallel scientific advice program could be beneficial for complex generic sponsors. • Source: Shutterstock

More from Generics

More from Biosimilars & Generics